Bristol-Myers Squibb (BMY) Tops Q2 EPS by 43c, Beats on Revenue; Offers FY26 Guidance

Bristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $2.04, $0.43 better than the analyst estimate of $1.61. Revenue for the quarter came in at $12.97 billion versus the consensus estimate of $11.71 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2026 EPS of $6.75-$7.00, versus the consensus of $6.34. Bristol-Myers Squibb sees FY2026 revenue of $49.5-50 billion, versus the consensus of $47.5 billion.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• Dyadic International, Inc. (DYAI) Misses Q2 EPS by 2c
• Fervo Energy Company (FRVO) Reports Q2 Loss of $0.38
• Arbutus Biopharma (ABUS) Reports In-Line Q2 EPS